Massachusetts Medical Society: Module 13 - The Medical Use of Marijuana in Inflammatory Bowel Disease

Module 13 - The Medical Use of Marijuana in Inflammatory Bowel Disease

Module 13 - The Medical Use of Marijuana in IBD

Editors' Note: Medical marijuana has become an important area of study in healthcare. Doctors and healthcare professionals must understand the medical, legal, and social issues to best respond to their patients' questions and attend to their needs. This content area is not intended to encourage or dissuade the use of medical marijuana, but has been created to provide a balanced portrayal of the research in this area.

Created by Meredith Fisher-Corn, MD and Stephen B. Corn, MD

Learning Objectives

After reading this material, a participant will be able to:

  • Explain the rationale for the use of cannabis in the treatment of inflammatory bowel disorders
  • Discuss the clinical studies evaluating the efficacy of cannabis therapy for the treatment of IBD
  • Describe the available clinical evidence for the use of cannabis in treatment of IBD and associated symptoms


Raphael Mechoulam, PhD,  Institute for Drug Research, Medical Faculty, Hebrew University, Jerusalem, Israel 
Timna Naftali, MD, Institute of Gastroenterology and Hepatology, Meir Medical Center, Kfar Saba, Israel

Alan Ehrlich, MD
Clinical Assoc. Professor, University of Massachusetts School of Medicine (UMMS)

Meredith Fisher-Corn, MD

Stephen B. Corn, MD
Founding Editor-in-Chief,

Course Fees

Massachusetts Medical Society (MMS) Member: $9.00
Non-MMS Member: $16.50
Allied Health Professionals: $7.20



CME Credit

. 75 AMA PRA Category 1 Credit™  

Accreditation Statement for Joint Providership
This activity has been planned and implemented in accordance with the accreditation requirements and
policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint 
providership of the Massachusetts Medical Society and The Answer Page, Inc. The 
Massachusetts Medical Society is accredited by the ACCME to provide continuing medical education for 

AMA Credit Designation Statement 
The Massachusetts Medical Society designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity meets the criteria for the Massachusetts board of Registration in Medicine for risk management study.

National Commission on Certification of Physician Assistants (NCCPA).

Physician Assistants may claim .75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME or a recognized state medical society.

Continuing Education Credit for Pharmacists
The Board of Registration in Pharmacy in Massachusetts, (BOARD), accepts three continuing education types:  ACPE,  AMA PRA Category 1 Credit , and continuing education activities approved by any State Board of Pharmacy. 

Click  here  for a list of all state Boards of Pharmacy. 

A score of 70% or higher is required to receive  AMA PRA Category 1 Credit(s)™.  

Activity Term

Original Release Date: June 15, 2017
Review Date: N/A
Termination Date: June 15, 2020

System requirements:

Windows, XP, Vista, 7, 8 
Mac OSX 10.6 higher 
Most modern browsers including: 
Firefox 18.0+ 
Chrome 26+ 
Safari 5+ 
Flash player is required for some Online CME courses. 

iOS devices beginning with OS version 5 or higher (includes, iPhone, ipad and iTouch devices) 
Android devices including tablets and phones. 
Windows RT and tablets on Windows 8 are also supported.


Copyright © 2018. Massachusetts Medical Society, 860 Winter Street, Waltham Woods Corporate Center, Waltham, MA 02451-1411

(781) 893-4610 | (781) 893-3800 | Member Information Hotline: (800) 322-2303 x7311